Imad Hariri, MD
Advanced Heart Failure and Transplant Cardiology · Toledo, OHNPI 1710249917
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Bayer at 58.4% of the total. 2025 is the largest year on record at $28,260, more than ten times the $2,379 reported in 2019.
Across 208 payments — averaging $180.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$22K
- Abbott$6K
- Pfizer$5K
- Merck$2K
- Abiomed$1K
- AstraZeneca$454
- plus $2K from 18 others
Across 11 payments — averaging $4041.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$44K
What the payments were for
- Consulting fees$8,18322%
- Speaking & faculty fees$13,26835%
- Travel & lodging$8,38222%
- Food & beverage$7,72821%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 31 | $21,934 |
| Abbott | 60 | $5,602 |
| Pfizer | 5 | $4,730 |
| Merck | 18 | $1,861 |
| Abiomed | 12 | $1,054 |
| AstraZeneca | 22 | $454 |
| Johnson & Johnson(2 entities) | 18 | $417 |
| Atricure, Inc. | 4 | $264 |
| Novo Nordisk | 3 | $234 |
| Novartis | 11 | $206 |
| Kestra Medical Technology Services, Inc. | 2 | $142 |
| United Therapeutics Corporation | 1 | $117 |
| Medtronic | 1 | $105 |
| Amgen | 4 | $96 |
| Alnylam Pharmaceuticals Inc. | 4 | $88 |
| Boehringer Ingelheim | 3 | $67 |
| Lifenet Health | 1 | $56 |
| Chiesi USA, Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $18 |
| Biotronik Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$21,325
- VYNDAQEL$3,713
- VERQUVO$1,314
- Ensite Cardiac Mapping System$1,050
- VYNDAMAX$1,005
- CardioMEMS HF System$1,004
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$945
- Impella$811
- CARDIOMEMS$542
- HeartMate 3 Left Ventricular Assist Device$302
- HeartMate 3 Left Ventricular Dev$261
- FARXIGA$125
- ATRICURE SYNERGY ABLATION SYSTEM$125
- ATRICURE CRYOSURGICAL SYSTEM$125
- XARELTO$120
- Wegovy$115
- CoreValve Evolut$105
How this compares
$37,575 in reported general payments places this provider in the 80th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 23 | $512,987 |
| EntrestoSacubitril/Valsartan | 278 | $272,499 |
| VyndaqelTafamidis Meglumine | 12 | $257,441 |
| JardianceEmpagliflozin | 219 | $231,408 |
| FarxigaDapagliflozin Propanediol | 138 | $112,170 |
| EliquisApixaban | 28 | $28,143 |
| KerendiaFinerenone | 20 | $15,152 |
| InpefaSotagliflozin | 20 | $11,758 |
| Eplerenone | 96 | $7,878 |
| Bumetanide | 154 | $7,400 |
| Metoprolol Succinate | 321 | $6,620 |
| Torsemide | 198 | $3,128 |
| Spironolactone | 351 | $2,168 |
| Valsartan | 59 | $1,460 |
| Carvedilol | 99 | $982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $4,730 | $798,57163 claims |
| NovartisEntresto | $206 | $272,499278 claims |
| Boehringer IngelheimJardiance | $67 | $231,408219 claims |
| AstraZenecaFarxiga | $454 | $112,170138 claims |
| BayerKerendia | $21,934 | $15,15220 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $20 | $11,75820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Toledo
- Laura MurphyToledo$1K
- Antoan PhamToledo$35
- William AbrahamColumbus$802K
- Rami KahwashColumbus$379K
- Eugene ChungCincinnati$297K
- Kenneth VarianAkron$170K
- Ankit BhatiaCincinnati$141K
- Rachel GarciaCincinnati$104K
- Sateesh KesariCincinnati$101K
- Sitaramesh EmaniCincinnati$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.